EKEvangelia Kontogeorgi

Evangelia Kontogeorgi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Evangelia Kontogeorgi has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) in Patients with Gynecological Malignancies: A Systematic Review

    by Aristotelis-Marios Koulakmanidis, Evangelia Kontogeorgi, Dimitrios Zacharakis, Anastasia Prodromidou, Ioakeim Sapantzoglou, Giuseppe Mascellino, Konstantinos Kypriotis, Nikolaos Kathopoulis, Dimos Sioutis, Charalampos Voros, et al.

    Aim: The purpose of this study was to investigate the safety, efficacy, and clinical outcomes of the vaginal natural orifice transluminal endoscopic surgery (vNOTES) technique in patients suffering from gynecological cancer. Methods: A systematic review of the literature was conducted from inception to October 2025 following the PRISMA guidelines. PubMed, Google Scholar, and the Cochrane Library were searched for studies investigating vNOTES in gynecological malignancies. Study quality was evaluated using the Newcastle–Ottawa Scale, the National Institute of Health and the Joanna Briggs Institute critical appraisal tools. Results: The search identified 11 observational cohort studies, 28 case series, and 22 case reports. A total of 926 patients with suspected or confirmed gynecologic malignancies underwent surgery via vNOTES approach. The combination of hysterectomy, bilateral salpingo-oophorectomy, and sentinel lymph node biopsy represented the most commonly performed surgical procedure. Endometrial cancer was the most frequent oncological indication. The included studies evaluated the perioperative outcomes, including operative time, estimated blood loss, lymph node assessment, conversion rates and complications. Conclusions: The vNOTES approach appeared to be feasible and at least non-inferior to standard surgical treatments for patients with early-stage gynecologic malignancies. However, the small sample sizes and heterogeneity among studies limit the strength of the evidence and preclude definitive conclusions.

  • Open Access

    Vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) for Gynecological Procedures in Obese Patients: A Systematic Review

    by Aristotelis-Marios Koulakmanidis, Christos Vrysis, Dimitrios Zacharakis, Evangelia Kontogeorgi, Ioakeim Sapantzoglou, Charalampos Voros, Athanasios Gkirgkinoudis, Christos Damaskos, Nikolaos Garmpis, Gerasimos Tsourouflis, et al.

    Aim: This study was conducted to determine the feasibility, safety, and clinical outcomes of the vaginal natural-orifice transluminal endoscopic surgery (vNOTES) approach in gynecology for obese patients. Methods: PubMed, Cochrane Library, and Google Scholar were searched, from inception to April 2025. A systematic review was performed following the PRISMA guidelines. Studies assessing the use of vNOTES for gynecological procedures in obese women were included. The quality of included articles was evaluated according to the Newcastle–Ottawa Scale. Results: The search yielded three retrospective cohort studies, one cross-sectional, and ten case series. The patients in the vNOTES group (n = 99) had statistically significant shorter operative times, reduced hospitalization, lower postoperative pain scores, fewer perioperative complications, and improved quality of life when compared to the laparoscopy group (n = 84). A study compared obese women to non-obese women undergoing vNOTES and found that operative times were longer in the obese group. Conversion to laparoscopy or laparotomy occurred in fewer than 5% of cases, and intraoperative and postoperative complication rates were low across all studies. Conclusions: vNOTES appears to be safe and potentially superior to other minimally invasive techniques. The small sample size of the case series and the lack of a sufficient number of comparative studies limit the strength of the conclusions.


  • Open Access

    Clinicopathological Predictors of Recurrence in Uterine Sarcomas—A Narrative Review

    by Emmanuel N. Kontomanolis, Ioakeim Sapantzoglou, Konstantinos Nikolettos, Evangelia Kontogeorgi, Vasiliki Lampraki, Dimitrios Papageorgiou, Paraskevas Perros, Zacharias Fasoulakis, Aristotelis-Marios Koulakmanidis, Maria-Anastasia Daskalaki, et al.

    Background: Sarcomas are a rare and biologically diverse group of malignant tumors that originate from mesenchymal tissues. They are characterized by a broad range of histopathological subtypes, varying clinical courses, and differing responses to treatment. This study seeks to clarify the clinicopathological and molecular predictors of recurrence in leiomyosarcomas, carcinosarcomas, and endometrial stromal sarcomas to enhance our understanding, thereby improving clinical knowledge, consultation practices, and the overall benefit for patients. Methods: A literature search was conducted utilizing PubMed/MEDLINE, Embase, Cochrane Library, and Scopus to execute a comprehensive structured narrative review of articles published up to 31 March 2025. Results: We summarize existing evidence on the clinical, histological, and molecular predictors of recurrence and poor prognosis for leiomyosarcomas, carcinosarcomas, and endometrial stromal sarcomas. While the stage, grade, tumor size, and novel molecular biomarkers are crucial high-risk parameters that have been associated with recurrence, existing data demonstrate contradictory results, indicating the need for further research. Conclusions: Recent advancements in next-generation sequencing have facilitated the identification of women at increased risk of recurrence, poor disease-free survival, and overall adverse prognosis. Stratifying this risk requires a comprehensive understanding of the clinical, histological, and molecular risk factors involved. Understanding these underlying factors is essential for effectively addressing the initial consultation, guiding management, and—considering the novel treatment modalities—individualizing the care provided to the affected women.


  • Open Access

    Clinicopathological Predictors of Recurrence in Uterine Sarcomas – A Narrative Review

    by Emmanuel N Kontomanolis, Ioakeim Sapantzoglou, Konstantinos Nikolettos, Evangelia Kontogeorgi, Vasiliki Lampraki, Dimitrios Papageorgiou, Paraskevas Perros, Zacharias Fasoulakis, Aristotelis-Marios Koulakmanidis, Maria Anastasia Daskalaki, et al.

    Background: Sarcomas are a rare and biologically diverse group of malignant tumors that originate from mesenchymal tissues. They are characterized by a broad range of histopathological subtypes, varying clinical courses, and differing responses to treatment. This study seeks to clarify the clinicopathological and molecular predictors of recurrence in leiomyosarcomas, carcinosarcomas, and endometrial stromal sarcomas to enhance our understanding, thereby improving clinical knowledge, consultation practices, and the overall patient benefit. Methods: A literature search was conducted utilizing PubMed/MEDLINE, Embase, Cochrane Library, and Scopus to execute a comprehensive structured narrative review of articles published until 31 March 2025 Results: We summarized the current evidence on clinical, histological and molecular predictors of recurrence and poor prognosis of leiomyosarcomas, carcinosarcomas and endometrial stromal sarcomas. The stage, the grade and the tumour size, as well as, novel molecular biomarkers constitute crucial high risk parameters that have been associated with recurrence but data, so far, demonstrate contradictory results with the need of further research deemed necessary. Conclusions: Recent advancements in next-generation sequencing have facilitated the identification of women at increased risk of recurrence, poor disease-free survival, and overall adverse prognosis. The stratification of this risk requires a comprehensive understanding of the clinical, histological, and molecular risk factors involved. An understanding of those underlying factors is essential for effectively addressing the initial consultation, guiding management, and, considering the novel treatment modalities, individualizing the care for affected women.


  • Open Access

    Pregnancy and COVID-19

    by Thomas Ntounis, Ioannis Prokopakis, Antonios Koutras, Zacharias Fasoulakis, Savia Pittokopitou, Asimina Valsamaki, Athanasios Chionis, Evangelia Kontogeorgi, Vasiliki Lampraki, Andria Peraki, et al.

    Evidence indicates that SARS-CoV-2 infection increases the likelihood of adverse pregnancy outcomes. Modifications in the circulatory, pulmonary, hormonal, and immunological pathways induced by pregnancy render pregnant women as a high-risk group. A growing body of research shows that SARS-CoV-2 infection during pregnancy is connected to a number of maternal complications, including pneumonia and intensive care unit (ICU) hospitalization. Miscarriages, stillbirth, preterm labor, as well as pre-eclampsia and intrauterine growth restriction are also among the most often documented fetal implications, particularly among expecting women who have significant COVID-19 symptoms, often affecting the timing and route of delivery. Thus, prevention of infection and pharmacological treatment options should aim to minimize the aforementioned risks and ameliorate maternal, obstetric and fetal/neonatal outcomes.